Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Nov 1, 2014 in Rheumatoid Arthritis | 0 comments

In a nutshell

This study investigated whether specific blood markers can predict if patients will be affected by rheumatoid arthritis-associated interstitial lung disease (RA-IDL).

Some background

Interstitial lung disease is a condition involving inflammation and scarring in the lungs. Patients with rheumatoid arthritis are at higher risk of developing interstitial lung disease (7-10% of patients will be affected). Therefore, it would be valuable if blood markers could predict which patients will be affected by RA-IDL.

Two potential markers are anti-cyclic citrullinated peptide antibody (anti-CCP2) and rheumatoid factor. Increases in both of these proteins can indicate more severe disease. Anti-CCP2 has also been linked to other conditions, including heart disease and type-1 diabetes, which can affect patients with rheumatoid arthritis.

Methods & findings

285 Chinese patients with rheumatoid arthritis were included in the study. Patients were examined for the presence of RA-IDL and blood samples were collected to measure anti-CCP2 and rheumatoid factor. Overall 24.9% of patients had RA-IDL. Patients with RA-IDL were significantly older and had longer disease duration than patients without RA-IDL.

Statistical analysis revealed that low, medium and high levels of anti-CCP2 were linked to the presence of RA-IDL. Low levels of blood anti-CCP2 increased the odds of having RA-IDL by 3.5 times compared to patients with no anti-CCP2. Moderate levels of anti-CCP2 increased the odds of having RA-IDL by 4.22 times and high levels of anti-CCP2 increased the odds of having RA-IDL by 2.96 times compared to patients with no anti-CCP2 in their blood samples.

After taking gender, age, disease duration, smoking, medication and other complications into account rheumatoid factor was not associated with RA-IDL.

The bottom line

The authors concluded that increased anti-CCP2 may be a good marker for diagnosing or predicting RA-IDL in patients with rheumatoid arthritis.

The fine print

As this study was undertaken in Chinese patients, genetic factors may have played a part. 

Published By :

PLOS ONE

Date :

Apr 17, 2014

Original Title :

Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis.

click here to get personalized updates